Literature DB >> 18825706

Abnormal neurological features predict poor survival and should preclude liver transplantation in patients with deoxyguanosine kinase deficiency.

David P Dimmock1, J Kay Dunn, Annette Feigenbaum, Anthony Rupar, Rita Horvath, Peter Freisinger, Bénédicte Mousson de Camaret, Lee-Jun Wong, Fernando Scaglia.   

Abstract

Deoxyguanosine kinase (DGUOK) deficiency is the commonest type of mitochondrial DNA depletion associated with a hepatocerebral phenotype. In this article, we evaluate predictors of survival and therapeutic options in patients with DGUOK deficiency. A systematic search of MEDLINE, LILAC, and SCIELO was carried out to identify peer-reviewed clinical trials, randomized controlled trials, meta-analyses, and other studies with clinical pertinence. DGUOK deficiency was searched with the terms dGK, DGUOK, mitochondrial DNA depletion, mtDNA, and hepatocerebral. Bibliographies of identified articles were reviewed for additional references. Thirteen identified studies met the inclusion criteria and were used in this study. The analysis revealed that DGUOK deficiency is associated with a variable clinical phenotype. Long-term survival is best predicted by the absence of profound hypotonia, significant psychomotor retardation, or nystagmus. In the presence of these features, there is increased mortality, and liver transplantation does not confer increased survival. In summary, liver transplantation appears to be futile in the presence of specific neurological signs or symptoms in patients affected with DGUOK deficiency. Conversely, in the absence of these neurological features, liver transplantation may be considered a potential treatment. (c) 2008 AASLD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18825706     DOI: 10.1002/lt.21556

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  24 in total

1.  Two patients with hepatic mtDNA depletion syndromes and marked elevations of S-adenosylmethionine and methionine.

Authors:  S Harvey Mudd; Conrad Wagner; Zigmund Luka; Sally P Stabler; Robert H Allen; Richard Schroer; Timothy Wood; Jing Wang; Lee-Jun Wong
Journal:  Mol Genet Metab       Date:  2011-11-12       Impact factor: 4.797

Review 2.  Mitochondrial medicine: to a new era of gene therapy for mitochondrial DNA mutations.

Authors:  Hélène Cwerman-Thibault; José-Alain Sahel; Marisol Corral-Debrinski
Journal:  J Inherit Metab Dis       Date:  2010-06-23       Impact factor: 4.982

3.  Potentially diagnostic electron paramagnetic resonance spectra elucidate the underlying mechanism of mitochondrial dysfunction in the deoxyguanosine kinase deficient rat model of a genetic mitochondrial DNA depletion syndrome.

Authors:  Brian Bennett; Daniel Helbling; Hui Meng; Jason Jarzembowski; Aron M Geurts; Marisa W Friederich; Johan L K Van Hove; Michael W Lawlor; David P Dimmock
Journal:  Free Radic Biol Med       Date:  2016-01-08       Impact factor: 7.376

Review 4.  Mitochondrial energetics and therapeutics.

Authors:  Douglas C Wallace; Weiwei Fan; Vincent Procaccio
Journal:  Annu Rev Pathol       Date:  2010       Impact factor: 23.472

Review 5.  Liver transplantation for pediatric inherited metabolic disorders: Considerations for indications, complications, and perioperative management.

Authors:  Kimihiko Oishi; Ronen Arnon; Melissa P Wasserstein; George A Diaz
Journal:  Pediatr Transplant       Date:  2016-06-21

6.  Neonatal liver failure due to deoxyguanosine kinase deficiency.

Authors:  Susana Nobre; Manuela Grazina; Francisco Silva; Carla Pinto; Isabel Gonçalves; Luísa Diogo
Journal:  BMJ Case Rep       Date:  2012-04-02

7.  Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.

Authors:  Sílvia Vilarinho; Sinan Sari; Güldal Yilmaz; Amy L Stiegler; Titus J Boggon; Dhanpat Jain; Gulen Akyol; Buket Dalgic; Murat Günel; Richard P Lifton
Journal:  Hepatology       Date:  2016-03-31       Impact factor: 17.425

Review 8.  Mitochondrial DNA depletion syndromes: review and updates of genetic basis, manifestations, and therapeutic options.

Authors:  Ayman W El-Hattab; Fernando Scaglia
Journal:  Neurotherapeutics       Date:  2013-04       Impact factor: 7.620

Review 9.  Gastrointestinal and hepatic manifestations of mitochondrial disorders.

Authors:  Shamima Rahman
Journal:  J Inherit Metab Dis       Date:  2013-05-15       Impact factor: 4.982

10.  A modern approach to the treatment of mitochondrial disease.

Authors:  Sumit Parikh; Russell Saneto; Marni J Falk; Irina Anselm; Bruce H Cohen; Richard Haas; The Mitochondrial Medicine Society
Journal:  Curr Treat Options Neurol       Date:  2009-11       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.